Phase 2 N=109 Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=134 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants
N/A N=42 Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Huntington's Disease
Primary: Quantitative Electroencephalography Absolute Delta Power. — 43.45; 10.11 microvolts squared — p=<0.0000001
Phase 3 N=128 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Chorea, Huntington
Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…
Phase 2 N=272 Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…
Phase 2 N=47 Study of WVE-003 in Patients With Huntington's Disease
Huntington Disease
Primary: Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug — 2; 1; 3; 3 Participants
N/A N=11 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
Huntington's Disease
Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)
Phase 2 N=35 Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Huntington Disease
Primary: Efficacy by UHDRS-TMS — -1.23; 0.84; 8.91 score on a scale/year
Phase 2 N=139 Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Huntington Chorea
Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…
Phase 4 N=50 Study of Memantine to Treat Huntington's Disease
Huntington's Disease
Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall)
N/A N=430 Dementia Symptom Management at Home Program
Dementia
Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale
Phase 2 N=10 Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
Huntington Disease
Primary: Change in PGC-1alpha RNA Expression — -0.02190716; 0.3160562; 0.07414876; 0.4800263 Log 2 fold change
Phase 3 N=114 Pilot Study of Minocycline in Huntington's Disease
Huntington Disease
Primary: Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method] — 1.55; 1.15 units on a scale
Phase 1 N=95 Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test and IS — 0.19; -0.12; -0.76; -0.24 Scores on a scale
Phase 2 N=69 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Huntington Disease
Primary: Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline — -3.3657; 0.0000 Z score…
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
Phase 3 N=119 Alternatives for Reducing Chorea in Huntington Disease
Chorea Associated With Huntington Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…
Phase 2 N=37 Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
Huntington's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 18; 14; 1; 1 participants
Phase 2 N=46 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
Huntington's Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) — 12; 3; 6; 6 Participants
N/A N=78 Electronic-health Application To Measure Outcomes REmotely Clinical Trial
Neurodegenerative Disease · Weight Loss · Amyotrophic Lateral Sclerosis
Primary: Estimated Mean Change in Weight From Baseline to 6 Months — -0.1; -0.2; -1.2 kg
Phase 2 N=6 Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Huntington Disease · Chorea
Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27
N/A N=370 GEnetic Counseling Through Virtual Visits in Parkinson's Disease
Parkinson Disease
Primary: Genetics Knowledge — 16; 17; 17; 16 score on a scale
N/A N=883 Barriers to Mental Healthcare Utilization in Parkinson's Disease
Parkinson's Disease · Depression · Anxiety
Primary: Most Commonly Reported Past Barrier to Mental Health Services: "Anyone in my Situation Would be Struggling" — 74.8 percentage of total respondents
Phase 3 N=90 First Time Use of SD-809 in Huntington Disease
Chorea
Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001
N/A N=56 In-Home Care for Patients With PSP and Related Disorders
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
Phase 1 N=118 HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Percent Change in HERV-K Level — -30.7 Percent change
N/A N=24 The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease
Huntington's Disease
Primary: Gait Parameters — 1.289; 1.292 meters per second
N/A N=50 Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
Latent Tuberculosis Infection
Primary: Completion of TBI Treatment — 45 Participants
Phase 2 N=10 Creatine Safety & Tolerability in Huntington's Disease
Huntington's Disease (HD)
Primary: Tolerability — 5 Participants
N/A N=80 Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
Alzheimer Disease · Dementia · Brain Diseases
Primary: Change in Caregiver Mastery — 12.6; 13; 13 units on a scale